https://www.live-feeds.com/feed/tango-reports-82-tumor-response-rate-in-trial-of-combo-therapy-for-advanced-pancreatic-cancerContinuously updated, source-cited coverage. https://www.live-feeds.com/feed/tango-reports-82-tumor-response-rate-in-trial-of-combo-therapy-for-advanced-pancreatic-cancerhttps://www.live-feeds.com/feed/tango-reports-82-tumor-response-rate-in-trial-of-combo-therapy-for-advanced-pancreatic-cancer#u159619Wed, 28 Oct 2026 09:11:37 +0000Tango Therapeutics reported an 82% objective response rate for its experimental combination therapy targeting advanced pancreatic cancer at the ESMO 2026 congress. The trial evaluated vopimetostat combined with daraxonrasib in previously treated patients carrying MTAP deletions and RAS mutations. Although the response rate dipped from an earlier 92% figure in a smaller cohort, the updated data included 22 evaluable patients. Tango announced plans to advance the combination into a global Phase III trial as a first-line treatment in the first half of 2027.Why it mattersPancreatic cancer remains